Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2013

View Archived Issues

Novel NOTCH3 gene mutation linked to CADASIL

Biomarkers identified for 90-day mortality after intracerebral hemorrhage

Blood pressure-lowering activity demonstrated for ARA-290

LGX-818 shows initial promise in solid tumors and melanoma

Zebrafish model/computational screening to accelerate drug discovery

The discovery of a first-in-class inhibitor of a major human oxidative stress pathway

PBI-4050 demonstrates promising antifibrotic properties in vivo

Genotype determines response to butyrate in patients with congenital chloride diarrhea

TissueGene-C therapy evaluated in patients with knee osteoarthritis

AVEO Oncology receives complete response letter for tivozanib NDA

BioLineRx enters collaboration with Jiangsu Chia-tai Tianqing Pharmaceutical

Concert Pharmaceuticals begins phase I trial of CTP-354

Discovery Labs responds to FDA request for clarification regarding Surfaxin specifications

Dynavax reports on FDA meeting for Heplisav

HemaQuest Pharmaceuticals completes enrollment in phase IIb HQK-1001 study

Neumedicines receives BARDA award for HemaMax

Centaurus BioPharma presents novel B-raf inhibitors

Trigemina begins phase II trial of TI-001 in chronic migraine

Seattle Genetics begins phase I/II trial of Adcetris in combination with bendamustine

Xenon Pharmaceuticals licenses XEN-701 from Isis Pharmaceuticals

Chinese team patents new EGFR inhibitors for cancer

Heptares Therapeutics designs novel M1 receptor agonists

New agents for the treatment of Coxsackie viral infections disclosed by Chinese group

KBP BioSciences presents new DP2 receptor antagonists

Global alliance initiated to share genomic and clinical data

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...